THE CRESCENTPHARMAGROUP

IntroductionMission StatementCrescent Pharma and the management team are committed to ensuring the manufacture of medicinal products to the highest quality, safety and efficacy by adhering to, and implementing quality systems in compliance with GMP and GDP

Vision StatementCrescent Pharma is focused on increasing the intellectual property and product portfolio to a range of 450 generic, new combination and branded products by 2020

Group Introduction

• Founded in 2003 Privately owned UK Medium Sized Business

• 2017 Turnover: 41 million GBP• 2017 Units Sold: 100 + million packs• Catalyst Pharma 50 top 10 (2nd) in fastest growing

pharmaceutical company category• In the top 1000 companies to inspire Europe 2017

in the London Stock Exchange• 19th in the Top 100 SME suppliers to the Central

Government in 2015/16• 195 active products including brands, generics

and medical devices (OTC) 288 granted MA’s• Development pipeline over 280 products, 90 filed,

68 ready to file• Exporting to 22 global markets• UK Manufacturing and robust supply chain• 78 UK Staff• Own UK wide MHRA approved distribution

network

Company Growth

• Capacity, Ambitionand appetite to continue aggressivegrowth strategy

• Target to have largest portfolio in terms of range in UK by 2020 on target for over 500 MA’s based on committed pipeline

• Market share minimum 30% target per product

• Established UK Generics Portfolio and generic brand, UK focused with growing global presence• Provide a unique service in UK generics industry, focused on price, service and continuity for our

customers• Specialise in own label and contract business 70 own labels, TESCO, Almus, Lloyds etc.• Purchased Remedeine Brand in 2013 from Napp• Over 113 NHS contracts• Department of Health Essential Medicine buffer contract awarded in 2016 over £15 million• Growing portfolio including a number of exclusive generics and OTC products. E.g. Glucosamine

sachets, Antibiotics, Licensed clove oil gel, Orlistat• Approx. 10 Semi exclusive lines• Own UK liquids plant purchased in Jan 2016• Own UK Antibiotic plant purchased in Jan 2016

• All stock control and orders controlled from Head Office site in Hampshire UK• Long shelf life and maximum product stability; Paracetamol 5 years, Ibuprofen 4 years etc.

(Added Value)• Hold 3 month buffer stocks for our contract customers in different geographical sites and provide

a virtual warehouse within the stock system which guarantees and secures the stock for our customers

• Capacity and Infrastructure in place to bid for more business

Supply Chain and Risk Management

• Master Control – First UK Generics company to purchase this system (fully integrated electronic quality management system)

• Bespoke stock Sage X3 GDP system with full stock status control• 24 hour temperature mapping and alarm system• Full barcode control• 4 registered QP’s• Dedicated Compliance manager• All quality staff based in the UK• Regulatory and Artwork team in UK

Quality Management System

• Focused on developing liquid, creams and gels• Development of new strengths and dosage forms• Development of herbal licensed products• Development of nursing home range• Acquisition of new OTC products and technologies• Acquisition of end of life brands

New Product Development

• Specialise in sales, marketing and distribution for licensed healthcare medicines and medical devices

• Experts in enhancing brand identity as well as product rebranding

• Proven track record of marketing to healthcare professionals resulting in products being available on prescription

• Branded range over 43 products

• Sage X3 Bespoke Pharma System• Full Wi-Fi Temperature mapping across the network• Full Bar Coding System• Batch Status control and customer virtual warehouses

Warehouses and Distribution

Andover Barnsley London

4,900 Pallets10,800 Pallets5.200 Pallets

UK Network

• Asset acquisition acquired in 2016• UK Based (London)• Capabilities: Liquid, Gel, Cream,

Specials, Suppositories, Eye drops, Anti Biotic tablet, Capsule and Dry Powder suspension

• Veterinary production capability• In house development• The site comprises of two separate

MHRA approved buildings:• QC Lab

1. The liquids production, office building, and QC Lab2. The antibiotic unit, and QC Lab

• Liquids Manufacturing: Single shift capacity 8.5 million bottles per annum• Site is approximately 30,000 square feet• MHRA Approved• Liquids, creams, gels, suppositories• Glass bottles, 100ml, 150ml, 300ml, 500ml, droppers, vials, aluminium tubes, pots• 100L, 500L, 1,500L and 5,000L batch sizes capability• QC Lab 4 x HPLC

Liquid Site

Liquid Site Plan• The Layout

Liquid Site Plan

• The Process

Liquid Site Plan• The Products

• Antibiotic unit: Capacity Single shift dry powder suspension 2.6 bottles per year• MHRA approved• 10,000 square feet• QC Lab 2 x HPLC

Antibiotic Site

Antibiotic Site Plan

• The Layout

Dry PowderSuspension

Antibiotic Site Plan

Tablets / Capsules

• The Process

Antibiotic Site Plan• The Products

THANKS